Fangzhou Jianke's 'Xingjie Large Model' Receives National Filing Approval, Powering AI-Driven Chronic Disease Management Under China's 'AI+' Initiative

Recently,“AI+Chronic Disease Management” industry leader Fangzhou Pharmaceutical (HKEX:06086) has completed the filing for its self-developed AI super brain, the “Xingjie Large Model,” as a generative artificial intelligence service with the Cyberspace Administration of China (Filing No.: Guangdong-XingJie-202509120089).On October 31, the Guangdong Province Large Model Filing Launch Conference (Phase I), themed “Filing Empowerment, Guangdong Innovation for the Future,” was successfully held in Shenzhen. Fangzhou Pharmaceutical was awarded the “Filing Certificate for Generative Artificial Intelligence Services.”

Figure: Fangzhou Pharmaceutical Awarded “Filing Certificate for Generative AI Services”

At the press conference, Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, stated that the successful launch of the Xingjie Large Model marks another significant milestone in Fangzhou Pharmaceutical’s practice within the “AI + Chronic Disease Management” sector.“True AI empowerment is never about piling on features, but about making health care proactive, predictive, and ubiquitous.”Building on this foundation, Fangzhou Pharmaceutical will continue to enrich the new ecosystem of AI+H2H (Hospital to Home) smart healthcare services (hereinafter referred to as the “AI+H2H Ecosystem”), striving to deeply integrate cutting-edge AI technologies with professional medical services, so that every user can enjoy smarter, more convenient, and more personalized health services.

“Xingjie Large Model” has completed national-level registration, marking a formal transition in the field of chronic disease management services from traditional passive Q&A-based support to a new era driven by AI-powered proactive insights and personalized solutions.Notably, Fangzhou Pharmaceutical is one of the few internet healthcare companies in the industry empowered by a “dual-model” strategy. The deployment of its two major models, the “Xingjie Large Model” and the “Xingshi Medical Large Model,” has laid a solid technological foundation for innovative development in the field of “AI + chronic disease management.”

Figure/Dr. Xie Fangmin, Founder, Chairman and CEO of Fangzhou Pharmaceutical, delivered a keynote presentation

Against the backdrop of increasingly complex demands for chronic disease management services, users’ core pain points are primarily concentrated in difficulties accessing medical consultations and purchasing medications, as well as poor treatment adherence. Fangzhou Pharmaceutical has recognized that users need more than just a tool to answer questions; they require a “partner” capable of deeply understanding their needs and providing one-stop solutions. Based on this insight, the Xingjie Large Language Model was developed.

As a key pillar of Fangzhou Pharmaceutical's AI+H2H ecosystem,The core capabilities of the Xingjie Large Model are built upon three innovative pillars: breakthroughs in technological foundations, innovation in application models, and leaps in operational efficiency, which collectively support an exceptional service experience.

Breakthroughs in the model’s technological foundation are reflected in its deep emotional perception and intent reasoning capabilities, enabling precise identification of user emotions and anticipation of needs to achieve “proactive answering.” Meanwhile, the model features an intelligent core capability that coordinates large and small models as well as tools, dynamically allocating resources based on scenarios to balance response speed and processing power.

In terms of application model innovation, the Xingjie large language model is driving a shift in services from function-heavy app interactions to experience-focused AI assistant interactions. By integrating multimodal technologies, it delivers a more natural user experience. Meanwhile, it evolves from passive question-and-answer systems into intelligent assistants capable of proactive decision-making and executing complex tasks, effectively alleviating business bottlenecks caused by shortages of resources such as physicians and customer service personnel.

Furthermore, the model has achieved a significant leap in operational efficiency: its knowledge base features self-evolving capabilities, automatically learning from and updating pharmaceutical and corporate knowledge derived from documents and historical conversations, thereby substantially reducing maintenance costs. The scope of service has also expanded from single customer service scenarios to cover the entire business chain, comprehensively enhancing the overall operational quality and efficiency of the enterprise.

Leveraging the aforementioned technical advantages, Fangzhou Pharmaceutical will further expand its application scenarios, driving the transformation of AI capabilities from underlying technologies to practical services.

The successful registration of the Xingjie Large Model marks a new milestone for Fangzhou Pharmaceutical’s AI ecosystem. Going forward, the company will leverage the Xingjie Large Model as the “foundation” to support its entire smart service ecosystem, while utilizing the Xingshi Medical Large Model as the “wheel” to work in synergy, enhancing full-cycle management service capabilities and providing robust support for the digital and intelligent implementation of specialized chronic disease management scenarios.

This year, Fangzhou Pharmaceutical’s “AI + Chronic Disease Management” ecosystem has continued to expand in scale and enhance in quality. The company has established strategic partnerships with leading domestic and international pharmaceutical enterprises, including Novo Nordisk, Innovent Biologics, and Fosun Pharma, to jointly create digital-intelligence benchmarks for “AI + Specialized Disease Management.” These efforts are driving the industry’s transition from “experience-based services” to a new stage characterized by “systematic and intelligent” solutions. Recently, Fangzhou Pharmaceutical has achieved closed-loop intelligent services in multiple specialized disease scenarios, such as “AI + Weight Management” and “AI + Psoriasis Management,” clearly demonstrating the empowering value of AI technology.

Specifically, in the field of weight management, Fangzhou Pharmaceutical integrates AI technology into the entire weight loss service process. It generates personalized weight loss recommendations for users seeking scientific weight loss plans through an AI health steward, and provides 24-hour professional consultations for obese patients with medication needs via an AI medication assistant. In the realm of psoriasis management, Fangzhou Pharmaceutical has further expanded the application boundaries of AI, constructing a new paradigm for full-cycle management that covers disease awareness, precise intervention, and long-term follow-up.

From the proposal of the “H2H” model to the current establishment of“Built on the Xingjie Large Model”、XingshiMedicalLarge models as the “wheel”AI+H2H New Ecosystem,Fangzhou Pharmaceutical’s digital-intelligence upgrade path clearly demonstrates the company’s forward-looking judgment on technological trends and its firm commitment to development.These cutting-edge explorations are not only a demonstration of the company’s technological prowess but also an inevitable outcome of its alignment with national policies.

Recently, at the press conference held by the Central Committee of the Communist Party of China on the spirit of the Fourth Plenary Session of the 20th Central Committee, the Ministry of Science and Technology explicitly stated that it would fully implement the “AI Plus” initiative to comprehensively empower a wide range of industries. Meanwhile, six departments, including the National Health Commission, jointly issued the Guiding Opinions, which clearly set forth requirements for “providing integrated management services for patients with multiple chronic conditions” and “strengthening digital and intelligent empowerment.”Fangzhou Pharmaceutical is responding to the nation’s expectations for development in technological innovation and chronic disease management services through concrete actions.

In the future, the company will leverage its two foundational models, “Xingjie” and “Xingshi,” to continuously develop innovative AI applications across the entire continuum of chronic disease management. By actively integrating into the national “AI+” initiative, the company aims to harness technological power to contribute to the realization of a Healthy China.